Literature DB >> 29284392

MRP4/ABCC4 As a New Therapeutic Target: Meta-Analysis to Determine cAMP Binding Sites as a Tool for Drug Design.

Agustín Yaneff1, Ana Sahores1, Natalia Gómez1, Alejandro Carozzo1, Carina Shayo2, Carlos Davio1.   

Abstract

MRP4 transports multiple endogenous and exogenous substances and is critical not only for detoxification but also in the homeostasis of several signaling molecules. Its dysregulation has been reported in numerous pathological disorders, thus MRP4 appears as an attractive therapeutic target. However, the efficacy of MRP4 inhibitors is still controversial. The design of specific pharmacological agents with the ability to selectively modulate the activity of this transporter or modify its affinity to certain substrates represents a challenge in current medicine and chemical biology. The first step in the long process of drug rational design is to identify the therapeutic target and characterize the mechanism by which it affects the given pathology. In order to develop a pharmacological agent with high specific activity, the second step is to systematically study the structure of the target and identify all the possible binding sites. Using available homology models and mutagenesis assays, in this review we recapitulate the up-to-date knowledge about MRP structure and aligned amino acid sequences to identify the candidate MRP4 residues where cyclic nucleotides bind. We have also listed the most relevant MRP inhibitors studied to date, considering drug safety and specificity for MRP4 in particular. This meta-analysis platform may serve as a basis for the future development of inhibitors of MRP4 cAMP specific transport. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Drug design; MRP inhibitors; MRP4/ABCC4; binding sites; cAMP; therapeutic-target.

Mesh:

Substances:

Year:  2019        PMID: 29284392     DOI: 10.2174/0929867325666171229133259

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  7 in total

Review 1.  Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer.

Authors:  Chengyi Mao; Xiaoxi Zeng; Chao Zhang; Yushang Yang; Xin Xiao; Siyuan Luan; Yonggang Zhang; Yong Yuan
Journal:  Front Cell Dev Biol       Date:  2021-02-11

2.  Study of Endogen Substrates, Drug Substrates and Inhibitors Binding Conformations on MRP4 and Its Variants by Molecular Docking and Molecular Dynamics.

Authors:  Edgardo Becerra; Giovanny Aguilera-Durán; Laura Berumen; Antonio Romo-Mancillas; Guadalupe García-Alcocer
Journal:  Molecules       Date:  2021-02-17       Impact factor: 4.411

Review 3.  Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer.

Authors:  Wenxiao Jiang; Guiqing Cai; Peter Hu; Yue Wang
Journal:  Acta Pharm Sin B       Date:  2021-02-10       Impact factor: 11.413

Review 4.  The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents.

Authors:  Jiabei Zhou; Yu Kang; Lu Chen; Hua Wang; Junqing Liu; Su Zeng; Lushan Yu
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

5.  Cyclic AMP efflux through MRP4 regulates actin dynamics signalling pathway and sperm motility in bovines.

Authors:  Nicolás Chiarante; Carlos A I Alonso; Jessica Plaza; Raquel Lottero-Leconte; Camila Arroyo-Salvo; Agustín Yaneff; Claudia E Osycka-Salut; Carlos Davio; Marcelo Miragaya; Silvina Perez-Martinez
Journal:  Sci Rep       Date:  2020-09-24       Impact factor: 4.379

6.  Diurnal expression of MRP4 in bone marrow cells underlies the dosing-time dependent changes in the oxaliplatin-induced myelotoxicity.

Authors:  Mizuki Kato; Yuya Tsurudome; Takumi Kanemitsu; Sai Yasukochi; Yuki Kanado; Takashi Ogino; Naoya Matsunaga; Satoru Koyanagi; Shigehiro Ohdo
Journal:  Sci Rep       Date:  2020-08-10       Impact factor: 4.379

7.  Multidrug transporter MRP4/ABCC4 as a key determinant of pancreatic cancer aggressiveness.

Authors:  A Sahores; A Carozzo; M May; N Gómez; N Di Siervi; M De Sousa Serro; A Yaneff; A Rodríguez-González; M Abba; C Shayo; C Davio
Journal:  Sci Rep       Date:  2020-08-26       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.